These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33439461)

  • 1. Implementation of Quality by Design (QbD) Principles in Regulatory Dossiers of Medicinal Products in the European Union (EU) Between 2014 and 2019.
    Ter Horst JP; Turimella SL; Metsers F; Zwiers A
    Ther Innov Regul Sci; 2021 May; 55(3):583-590. PubMed ID: 33439461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summary of the EMA Joint Regulators/Industry QbD workshop (London, UK; 28-29 January 2014).
    Cook G; France G; Holte Ø; Lorenti G; Tainsh D
    PDA J Pharm Sci Technol; 2016; 70(2):163-76. PubMed ID: 26797977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Question-based review for pharmaceutical development: An enhanced quality approach.
    Simões A; Veiga F; Vitorino C
    Eur J Pharm Biopharm; 2024 Feb; 195():114174. PubMed ID: 38160986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementing quality by design for biotech products: Are regulators on track?
    Luciani F; Galluzzo S; Gaggioli A; Kruse NA; Venneugues P; Schneider CK; Pini C; Melchiorri D
    MAbs; 2015; 7(3):451-5. PubMed ID: 25853461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality by design (QbD) approach in marketing authorization procedures of Non-Biological Complex Drugs: A critical evaluation.
    Zagalo DM; Sousa J; Simões S
    Eur J Pharm Biopharm; 2022 Sep; 178():1-24. PubMed ID: 35908664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk-based Process Development of Biosimilars as Part of the Quality by Design Paradigm.
    Zalai D; Dietzsch C; Herwig C
    PDA J Pharm Sci Technol; 2013; 67(6):569-80. PubMed ID: 24265299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality by design (QbD) approaches in current pharmaceutical set-up.
    Mishra V; Thakur S; Patil A; Shukla A
    Expert Opin Drug Deliv; 2018 Aug; 15(8):737-758. PubMed ID: 30044646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical product development: A quality by design approach.
    Pramod K; Tahir MA; Charoo NA; Ansari SH; Ali J
    Int J Pharm Investig; 2016; 6(3):129-38. PubMed ID: 27606256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review Experiences and Regulatory Challenges for Pharmaceutical Development in Japan Using a Quality-by-Design Approach.
    Kuno K; Toyoshima S
    Ther Innov Regul Sci; 2016 May; 50(3):368-374. PubMed ID: 30227068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical review on the Environmental Risk Assessment of medicinal products for human use in the centralised procedure.
    Caneva L; Bonelli M; Papaluca-Amati M; Vidal JM
    Regul Toxicol Pharmacol; 2014 Apr; 68(3):312-6. PubMed ID: 24447908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality-by-design: are we there yet?
    Cook J; Cruañes MT; Gupta M; Riley S; Crison J
    AAPS PharmSciTech; 2014 Feb; 15(1):140-8. PubMed ID: 24218058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports.
    Köhler M; Haag S; Biester K; Brockhaus AC; McGauran N; Grouven U; Kölsch H; Seay U; Hörn H; Moritz G; Staeck K; Wieseler B
    BMJ; 2015 Feb; 350():h796. PubMed ID: 25722024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing paradigms in bioequivalence trials submitted to the EMA for evaluation - A clinical and regulatory perspective.
    Refalo N; Chetcuti D; Tanti A; Serracino-Inglott A; Borg JJ
    Saudi Pharm J; 2017 Feb; 25(2):280-289. PubMed ID: 28344480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A full-document analysis of the semantic relation between European Public Assessment Reports and EMA guidelines using a BERT language model.
    Bergman E; Pasmooij AMG; Mol PGM; Westman G
    PLoS One; 2023; 18(12):e0294560. PubMed ID: 38100432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Quality by Design Development on the Review Period of New Drug Approval and Product Quality in Japan.
    Kajiwara E; Kamizato H; Shikano M
    Ther Innov Regul Sci; 2020 Sep; 54(5):1192-1198. PubMed ID: 32865801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roadmap for implementation of quality by design (QbD) for biotechnology products.
    Rathore AS
    Trends Biotechnol; 2009 Sep; 27(9):546-53. PubMed ID: 19647883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European regulation model for herbal medicine: The assessment of the EU monograph and the safety and efficacy evaluation in marketing authorization or registration in Member States.
    Qu L; Zou W; Wang Y; Wang M
    Phytomedicine; 2018 Mar; 42():219-225. PubMed ID: 29655689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency's Committee for Medicinal Products for Human Use.
    Cilia M; Ruiz S; Richardson P; Salmonson T; Serracino-Inglott A; Wirth F; Borg JJ
    AAPS PharmSciTech; 2018 Feb; 19(2):489-511. PubMed ID: 29027130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dossier for marketing authorization in the European union.
    Todić M
    Bosn J Basic Med Sci; 2003 Mar; 3(1):56-60. PubMed ID: 16209669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.